Royalty Pharma PLC - Class A (RPRX) closed at $69.45 on November 10, 2026, up 1.0% from the previous close, on volume of 2,884,786 shares (30-day average 3,223,167).
Data as of November 10, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 9, 2026 | Diagonal Call Spread | 20-Nov : 18-Dec-2665 : 67.5 C | 396 |
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 9, 2026. See the 10 largest for 30, 60 and 90 days
Royalty Pharma Earnings Call Highlights Strong Growth
TipRanks (Mon, 9-Nov 7:16 PM ET)
Novartis is said to be abandoning Ionis heart drug after late-stage trial setback
Seeking Alpha News (Sat, 7-Nov 11:36 AM ET)
BofA adds Nvidia, Microsoft, Bajaj Auto to its Global Contenders list
Seeking Alpha News (Thu, 5-Nov 9:22 AM ET)
TipRanks (Thu, 5-Nov 8:41 AM ET)
Royalty Pharma reports third quarter 2026 results
Globe Newswire (Wed, 4-Nov 7:00 AM ET)
Royalty Pharma declares fourth quarter 2026 dividend
Globe Newswire (Fri, 16-Oct 8:00 AM ET)
Royalty Pharma to announce third quarter 2026 financial results on November 4, 2026
Globe Newswire (Fri, 9-Oct 8:50 AM ET)
Globe Newswire (Tue, 15-Sep 4:35 PM ET)
Royalty Pharma to present at upcoming investor conferences
Globe Newswire (Wed, 9-Sep 4:05 PM ET)
Royalty Pharma announces update on Novartis' Phase 3 topline results for pelacarsen
Globe Newswire (Fri, 4-Sep 7:05 PM ET)
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Royalty Pharma PLC - Class A trades on the NASDAQ stock market under the symbol RPRX.
As of November 10, 2026, RPRX stock price climbed to $69.45 with 2,884,786 million shares trading.
RPRX has a beta of -0.04, meaning it tends to be less sensitive to market movements. RPRX has a correlation of 0.00 to the broad based SPY ETF.
RPRX has a market cap of $30.92 billion. This is considered a Large Cap stock.
Last quarter Royalty Pharma PLC - Class A reported $690 million in Revenue and $1.21 earnings per share. This fell short of revenue expectation by $-193 million and exceeded earnings estimates by $.03.
In the last 3 years, RPRX traded as high as $69.77 and as low as $24.05.
The top ETF exchange traded funds that RPRX belongs to (by Net Assets): VXF, VFLO, IWR, VYM, IHE.
RPRX has outperformed the market in the last year with a price return of +82.5% while the SPY ETF gained +12.9%. RPRX has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +22.7% and +7.2%, respectively, while the SPY returned -2.8% and -2.0%, respectively.
RPRX support price is $67.57 and resistance is $69.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RPRX shares will trade within this expected range on the day.
